Table 1 Subject characteristics
From: Characterization and inhibition of inflammasome responses in severe and non-severe asthma
Asthma status | Pairwise comparisons | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Characteristic | Class or Statistic | Healthy (N = 39) | Non severe (NSA; N = 59) | Severe (SA[S]; N = 36) | Severe exacerbating (SA[E]; N = 17) | Overall P value | NSA vs Healthy | SA(S) vs Healthy | SA(S) vs NSA | SA(E) vs SA(S) |
Age (years) | Mean (SD) | 45.0 (17.6) | 52.1 (17.2) | 62.9 (14.1) | 58.0 (18.5) | < 0.001 | 0.042 | < 0.001 | 0.003 | 0.318 |
Sex | Female | 28 (72%) | 42 (71%) | 17 (47%) | 11 (65%) | 0.079 | 0.948 | 0.030 | 0.020 | 0.234 |
Male | 11 (28%) | 17 (28%) | 19 (53%) | 6 (35%) | ||||||
Race | White | 38 (97%) | 50 (85%) | 34 (94%) | 17 (100%) | 0.089 | 0.048 | 0.470 | 0.197 | 1.000 |
Other | 1 (2.6%) | 9 (15%) | 2 (5.6%) | |||||||
BMI, kg/m2 | Mean (SD) | 28.5 (5.8) | 29.9 (6.3) | 29.7 (7.8) | 30.6 (8.4) | 0.668 | 0.257 | 0.444 | 0.877 | 0.696 |
Obesity status | Non-obese | 16 (41%) | 13 (22%) | 10 (28%) | 6 (35%) | 0.079 | 0.044 | 0.228 | 0.526 | 0.578 |
Obese | 23 (59%) | 46 (78%) | 26 (72%) | 11 (65%) | ||||||
Asthma characteristics | ||||||||||
Age of symptom onset, years | Median (Q1, Q3) | N/A | 12.0 (4.0, 27.5) | 7.0 (3.5, 35.0) | 11.0 (5.0, 28.5) | 0.789 | N/A | N/A | 0.657 | 0.454 |
Mean (SD) | N/A | 17.1 (16.5) | 18.9 (22.0) | 20.4 (20.9) | 0.792 | N/A | N/A | 0.655 | 0.804 | |
Mean ACQ-6 | Median (Q1, Q3) | N/A | 0.67 (0.33, 1.17) | 1.17 (0.42, 1.84) | 2.50 (1.17, 3.50) | 0.001 | N/A | N/A | 0.036 | 0.007 |
Mean (SD) | N/A | 0.89 (0.81) | 1.30 (1.02) | 2.28 (1.48) | < 0.001 | N/A | N/A | 0.054 | 0.023 | |
Asthma control (N, %) (ACQ-6 classification) | > 1.50 0.75–1.50 < 0.75 | N/A | 10 (17%) 18 (31%) 30 (52%) | 12 (33%) 10 (28%) 14 (39%) | 11 (65%) 2 (12%) 4 (24%) | 0.005 | N/A | N/A | 0.179 | 0.094 |
Exacerbations, past 12 months | ||||||||||
Number of ED visits (N, %) | 0 1 ≥2 | N/A | 53 (93%) 3 (5.3%) 1 (1.8%) | 33 (94%) 1 (2.9%) 1 (2.9%) | 13 (76%) 2 (12%) 2 (12%) | 0.117 | N/A | N/A | 1.000 | 0.103 |
Number of hospitalizations (N, %) | 0 1 ≥2 | N/A | 53 (93%) 3 (5.3%) 1 (1.8%) | 33 (94%) 2 (5.7%) | 14 (82%) 1 (5.9%) 2 (12%) | 0.248 | N/A | N/A | 1.000 | 0.131 |
Number of unscheduled Dr visits (N, %) | 0 1 ≥ 2 | N/A | 39 (68%) 10 (18%) 8 (14%) | 24 (69%) 4 (11%) 7 (20%) | 4 (24%) 3 (18%) 10 (59%) | 0.002 | N/A | N/A | 0.650 | 0.004 |
Number of OCS courses (N, %) | 0 1 ≥2 | N/A | 37 (65%) 12 (21%) 8 (14%) | 14 (40%) 4 (11%) 17 (49%) | 2 (12%) 3 (18%) 12 (71%) | < 0.001 | N/A | N/A | 0.002 | 0.117 |
Lung function | ||||||||||
FEV1preb2pp | Mean (SD) | 98.95 (12.04) | 82.90 (14.79) | 66.76 (19.03) | 67.57 (17.75) | < 0.001 | < 0.001 | < 0.001 | < 0.001 | 0.886 |
FVCpreb2pp | Mean (SD) | 100.95 (12.55) | 91.89 (14.47) | 81.45 (16.27) | 78.84 (15.14) | < 0.001 | 0.002 | < 0.001 | 0.002 | 0.591 |
FEV1/FVC, % | Mean (SD) | 77.51 (14.90) | 72.32 (9.85) | 63.54 (12.72) | 67.55 (10.29) | < 0.001 | 0.042 | < 0.001 | < 0.001 | 0.274 |
Sputum inflammatory markers | ||||||||||
Sputum eosinophils, % | Mean (SD) | 0.28 (0.38) | 4.76 (9.92) | 6.14 (12.35) | 5.50 (6.61) | 0.459 | 0.007 | 0.001 | 0.254 | 0.954 |
Total eosinophils (× 10^6/mL) | Mean (SD) | 0.01 (0.02) | 0.39 (1.17) | 0.42 (0.66) | 0.22 (0.22) | 0.688 | 0.012 | 0.004 | 0.204 | 0.534 |
Sputum neutrophils, % | Mean (SD) | 32.30 (24.35) | 35.61 (25.92) | 44.52 (27.99) | 41.23 (25.64) | 0.506 | 0.714 | 0.244 | 0.204 | 0.746 |
Total neutrophils (× 10^6/mL) | Mean (SD) | 2.02 (2.41) | 3.59 (5.40) | 4.59 (7.07) | 3.31 (4.84) | 0.712 | 0.902 | 0.423 | 0.345 | 0.885 |
Total cell count (× 10^6/mL) | Mean (SD) | 5.04 (3.48) | 6.47 (6.23) | 9.17 (8.54) | 6.34 (4.73) | 0.025 | 0.552 | 0.117 | 0.125 | 0.248 |
Asthma inflammatory phenotype (N, %) | Eosinophilic Non-eosinophilic | 9 (100%) | 14 (33%) 29 (67%) | 10 (45%) 12 (55%) | 6 (55%) 5 (45%) | 0.037 | 0.092 | 0.030 | 0.226 | 0.451 |